Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Depression (US)
Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and feelings of worthlessness. The prevalence of bipolar depression among BPD patients, combined with its negative effects, makes the management of depressive episodes a high priority in BPD treatment. Current treatment options are limited; only a few drugs are FDA-approved to treat bipolar depression, and other drugs used for this purpose may have serious side effects, as in the case of lithium and lamotrigine, or limited efficacy. Treatment may be individualized, and psychiatrists usually try different drugs/combinations in nonresponsive patients. This Treatment Algorithms: Claims Data Analysis report provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for bipolar depression.
Questions answered
- What shares do key therapies and brands garner by line of therapy in newly diagnosed bipolar depression patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed bipolar depression patients?
- How have AbbVie’s Vraylar and Intra-Cellular Therapies’ Caplyta been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of bipolar depression patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of bipolar depression patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key drugs: Lithium, lamotrigine, lurasidone, Vraylar, Caplyta, Trintellix, sertraline, quetiapine, olanzapine/fluoxetine
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business. Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
